Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
40,656,241
-
Shares change
-
-7,084,519
-
Total reported value, excl. options
-
$63,017,852
-
Value change
-
-$11,756,469
-
Put/Call ratio
-
82%
-
Number of buys
-
31
-
Number of sells
-
44
-
Price
-
$1.55
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q1 2025
As of 31 Mar 2025 Black Diamond Therapeutics, Inc. - Common Stock (BDTX) had 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 40,656,241 shares of stock of the company.
Largest 10 holders included T. Rowe Price Investment Management, Inc., Vestal Point Capital, LP, NEA Management Company, LLC, BlackRock, Inc., Bellevue Group AG, VANGUARD GROUP INC, TANG CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, Siren, L.L.C., and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 105 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.